HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

nafamostat

inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; RN given refers to parent cpd; structure in first source

Also Known As:

6'-amidino-2-naphthyl 4-guanidinobenzoate; FUT 175; FUT-175; nafamostat dihydrochloride; nafamostat mesilate; nafamostat mesylate; nafamstat mesilate; Benzoic acid, 4-((aminoiminomethyl)amino)-, 6-(aminoiminomethyl)-2-naphthalenyl ester, dihydrochloride

Networked: 244 relevant articles (40 outcomes, 41 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 58
- Amidines: 11
  - Guanidines: 20
    - nafamostat: 244

Experts

1.	Uwagawa, Tadashi: 14 articles (01/2016 - 05/2007)
2.	Yanaga, Katsuhiko: 13 articles (01/2016 - 08/2009)
3.	Fujiwara, Yuki: 11 articles (01/2016 - 10/2010)
4.	Furukawa, Kenei: 10 articles (01/2016 - 10/2010)
5.	Shiba, Hiroaki: 10 articles (01/2016 - 10/2010)
6.	Misawa, Takeyuki: 10 articles (02/2015 - 08/2009)
7.	Ohashi, Toya: 9 articles (01/2016 - 10/2010)
8.	Haruki, Koichiro: 8 articles (01/2016 - 07/2011)
9.	Iwase, Ryota: 6 articles (01/2016 - 11/2012)
10.	Ranieri, Girolamo: 4 articles (10/2015 - 01/2013)

Related Diseases

1.	Pancreatitis 11/01/2011 - "Is high-dose nafamostat mesilate effective for the prevention of post-ERCP pancreatitis, especially in high-risk patients?" 11/01/2011 - "Nafamostat mesilate prophylaxis (20 or 50 mg) is effective in preventing post-ERCP pancreatitis. " 02/01/1992 - "FUT-175 showed protective effects on the course of severe acute pancreatitis only when given prophylactically at the beginning of the pancreatitis induced by the CDE diet." 04/01/2009 - "Nafamostat mesylate prophylaxis is partially effective in preventing post-ERCP pancreatitis. " 05/01/2015 - "We aimed to evaluate the efficacy of nafamostat on the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). "
2.	Pancreatic Neoplasms (Pancreatic Cancer) 10/01/2010 - "The aim of this study is to evaluate the therapeutic efficacy of nafamostat mesilate against pancreatic cancer. " 07/01/2011 - "In conclusion, adenovirus vector-mediated TNF-α gene therapy combined with nafamostat mesilate was effective for pancreatic cancer in mice." 09/01/2011 - "In vivo, the efficacy of nafamostat mesilate treatment was assessed using peritoneal dissemination of pancreatic cancer in mice. " 09/01/2013 - "We previously reported that nafamostat mesylate inhibited NF-κB activation and induced apoptosis in pancreatic cancer. " 05/01/2011 - "We previously reported nafamostat mesilate (FUT175) inhibits NF-κB activation and promotes apoptosis in pancreatic cancer. "
3.	Hemorrhage 01/01/2014 - "Hence, nafamostat mesilate may be used as an effective and safe anticoagulant, without increasing the risk of major bleeding complications, in patients prone to bleeding. " 11/01/1993 - "A prospective, randomized trial was performed to assess the efficacy of FUT-175 in the reduction of postoperative bleeding tendency. " 01/01/2014 - "Hence, we conducted a prospective, randomized controlled study investigating the effect of nafamostat mesilate on mortality, CRRT filter life span and adverse events in patients with bleeding tendency. " 01/01/2014 - "Nafamostat mesilate may be one of the risk factors for spontaneous retroperitoneal bleeding." 03/01/2013 - "Although nafamostat mesilate induced activated partial thromboplastin time prolongation in 11 circuits (5.4%), bleeding episodes were not increased. "
4.	Shock 02/01/1997 - "The results indicate that inadequate tissue perfusion in shock stimulates blood coagulation and that nafamostat mesilate might be beneficial in decreasing excessive blood coagulation." 04/01/1991 - "Nafamostat Mesilate given as therapy significantly improved the hemodynamic parameters, and prevented the animals from developing shock. " 05/01/2003 - "Likewise, T/HS-induced intestinal villus injury was less in the nafamostat-treated shock rats (P < 0.05). " 04/01/1988 - "[Effect of FUT-175 on endotoxin-induced shock in the dog]." 01/01/1982 - "The minimal effective dose of FUT-175 in systemic Forssman shock in guinea pigs was 6.25 mg/kg i.p. "
5.	Stroke (Strokes) 04/01/2012 - "This study tested whether nafamostat mesilate is associated with perioperative ischemic stroke. " 11/01/2014 - "Nafamostat mesilate, administered in conjunction with low-dose heparinization, served as an effective anticoagulant for early surgery in patients with AIE complicated by stroke, and caused no further deterioration of the cerebral lesions." 04/01/2012 - "Of the 190 (21.8%) patients who received nafamostat mesilate, 1 (0.5%) suffered ischemic stroke compared with 10 (1.5%) in 680 patients without nafamostat mesilate (Fisher exact test; p = 0.47; regression analysis; odds ratio, 0.35; 95% confidence interval, 0.45-2.8; p = 0.32); 3 (1.6%) patients with nafamostat mesilate died postoperatively within 30 days compared with 11 (1.6%) without nafamostat mesilate (Fisher exact test; p > 0.99, regression analysis; odds ratio, 0.98; 95% confidence interval, 0.27-3.5; p = 0.97). " 04/01/2012 - "The authors retrospectively identified the patients who received nafamostat mesilate and who suffered symptomatic ischemic stroke within 30 postoperative days. " 11/01/2014 - "Efficacy of nafamostat mesilate as anticoagulation during cardiopulmonary bypass for early surgery in patients with active infective endocarditis complicated by stroke."

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	Serine Proteases (Serine Protease)
3.	Complement System Proteins (Complement)
4.	Gabexate (Foy)
5.	Heparin (Liquaemin)
6.	gemcitabine
7.	Dacarbazine (DIC)
8.	Caerulein (Ceruletide)
9.	Trypsin
10.	urinastatin (MR 20)

Related Therapies and Procedures

1.	Intra-Arterial Infusions
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Transplants (Transplant)
4.	Extracorporeal Membrane Oxygenation (ECMO)
5.	Resuscitation